Gene therapy using autologous or allogeneic cells offers promising possibilities to treat inherited and acquired diseases, ideally leading to a long-lasting therapeutic correction. This article summarizes efforts that use integrating vectors derived from retroviruses and transposons, and briefly explains integrating vector biology and integration site analysis and recent successful application of this technology in clinical trials. Moreover, outlined is how these vectors can be used for cancer gene discovery and clonal tracking of benign and malignant hematopoiesis to gain insights into the dynamics of hematopoiesis.
Key points
- •
In addition to the integration site preference, vector architecture (SIN vs LTR-driven vectors) and cargo have a major risk-benefit impact.
- •
The retrovirus- and transposon-based vector toolbox is indispensable for several applications and clinical trials.
- •
Integrating vectors create an integration site tag, which is used to monitor hematopoietic dynamics in healthy and malignant cells.

Stay updated, free articles. Join our Telegram channel

Full access? Get Clinical Tree


